Aradigm (ARDM) Stock Rating Lowered by Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services lowered shares of Aradigm (NASDAQ:ARDM) from a buy rating to a neutral rating in a research note issued to investors on Friday, Marketbeat reports.
Several other equities research analysts also recently issued reports on the company. Zacks Investment Research downgraded Aradigm from a buy rating to a hold rating in a report on Tuesday, October 17th. ValuEngine upgraded Aradigm from a sell rating to a hold rating in a report on Wednesday.
Shares of Aradigm (NASDAQ:ARDM) traded down $1.16 during trading hours on Friday, hitting $2.26. The stock had a trading volume of 2,664,730 shares, compared to its average volume of 425,228. The company has a debt-to-equity ratio of -1.59, a current ratio of 1.65 and a quick ratio of 1.65. Aradigm has a one year low of $0.78 and a one year high of $7.35. The firm has a market capitalization of $51.88, a price-to-earnings ratio of -2.31 and a beta of 1.57.
A hedge fund recently bought a new stake in Aradigm stock. Jane Street Group LLC purchased a new position in shares of Aradigm Corporation (NASDAQ:ARDM) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,025 shares of the company’s stock, valued at approximately $122,000. Jane Street Group LLC owned approximately 0.19% of Aradigm at the end of the most recent quarter. 32.02% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/13/aradigm-ardm-stock-rating-lowered-by-ladenburg-thalmann-financial-services.html.
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Stock Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related stocks with our FREE daily email newsletter.